Long-Term Illness in Adults Hospitalized for Respiratory Syncytial Virus Disease, United States, February 2022-September 2023

Document Type

Article

Publication Date

12-1-2025

Publication Title

Emerging infectious diseases

Keywords

Humans, Respiratory Syncytial Virus Infections, Male, Hospitalization, Female, Middle Aged, Quality of Life, Adult, COVID-19, United States, Aged, SARS-CoV-2, Young Adult, Respiratory Syncytial Virus, Human, Aged, 80 and over

Abstract

Respiratory syncytial virus (RSV) can cause severe illness, but little is known about long-term consequences in hospitalized adults. We surveyed adults (>18 years of age) who survived hospitalization for RSV or COVID-19 during February 2022-September 2023 about physical functioning and quality of life; surveys were conducted 6-12 months after hospitalization. We compared outcomes after RSV hospitalization by age (< 60 vs. >60 years) and to those hospitalized for COVID-19 by using multivariable regression models. Among 146 adults hospitalized with RSV, 27.4% reported severe breathlessness and 21.9% poor quality of life at follow-up. Few differences were seen in posthospital illness by age. After adjustment, participants with RSV had 1.81 (95% CI 1.08-3.04) times increased odds of worse dyspnea than did those with COVID-19. Participants reported functional and quality of life impairments after RSV hospitalization, regardless of age, and a postdischarge sequelae constellation similar to that for those hospitalized for COVID-19.

Medical Subject Headings

Humans; Respiratory Syncytial Virus Infections; Male; Hospitalization; Female; Middle Aged; Quality of Life; Adult; COVID-19; United States; Aged; SARS-CoV-2; Young Adult; Respiratory Syncytial Virus, Human; Aged, 80 and over

PubMed ID

41570181

Volume

31

Issue

14

First Page

20

Last Page

29

Share

COinS